Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Sprout Pharmaceuticals, Inc.

Ralf Lotz

Frank Himmelsbach

Matthias Eckhardt

Elke Langkopf

Michael Mark

Roland Maier

Dirk Stenkamp

Klaus Rudolf

Birgit Jung

Stephan Georg Mueller

Gerald Juergen Roth

Thorsten Lehmann-Lintz

Mohammad Tadayyon

Philipp Lustenberger

Marcus Schindler

Leo Thomas

Armin Heckel

Thorsten K Oost

Joerg Kley

Kirsten Arndt

Markus Ostermeier

Martin Lenter

Fabio Paleari

Heike-Andrea Wieland

Astrid Volz

Paleari Fabio

The present invention relates to substituted xanthines of general formula wherein Rto Rare as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Pyridone and pyridazinone derivatives that are active against the melanin-concentrating hormone (MCH) and useful as anti-obesity pharmaceuticals.

Pyridone and pyridazinone derivatives as anti-obesity agents

The present invention relates to spirocyclic heterocycles of general formula (I) the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways, and the preparation thereof.

Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production

The present invention pertains to a compound of formula (I) wherein R, R, R, and Rare each hydrogen or sulfate monoester with the proviso that R, R, R, and Rcannot simultaneously be hydrogen, processess for their preparation and their use as pharmaceuticals in the treatment of CNS disorders.

Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity

The present invention relates to cyclohexyloxy-substituted heterocycles of general formula (I) the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways and the preparation thereof.

Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them

The present invention relates to compounds of general formula I wherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R, R, have the meanings given in claim. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

Pyridone derivates with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to bicyclic heterocycles of general formula wherein

Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof

Xanthine derivates, their preparation and their use in pharmaceutical compositions

Disclosed are substituted xanthines of general formula wherein Rto Rare defined hereinbelow, the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions

Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R, and Rhave the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

Growing community of inventors

Schemmerhofen, Germany

Ralf Lotz